EP300

Across TCGA pan-cancer cohorts, EP300 mass-spec protein is linked to patient survival in 3 of 34 cancer types, making it a survival-associated EP300 data layer compared with 22 for mass-spec protein and 10 for mutation status.

The strongest signal is observed in head and neck squamous cell carcinoma (HNSC), where higher EP300 mass-spec protein is associated with worse overall survival. In most high-consensus cancer types, elevated EP300 expression acts as an unfavorable survival marker, although some lineages such as GBM and CCRCC show a favorable association.

HNSC, GBM, and CCRCC are the cancer types where EP300 mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
HNSC	OS	Tertile	III,IV	0.747	0.906	.018	20	view →
GBM	OS	Median	All	0.515	0.278	.003	14	view →
CCRCC	DFS	Tertile	III,IV	0.887	0.198	.024	5	view →

Pink = unfavorable, green = favorable. Showing the 3 strongest of 3 lineages.

EP300–HNSC (OS)

Open the HNSC breakdown →